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OBJECTIVE: To evaluate the benefits and harms of
discontinuation of oxytocin after the active phase of
labor is reached.
DATA SOURCES: Electronic databases (ie, MEDLINE,
Scopus, ClinicalTrials.gov, EMBASE, ScienceDirect, the
Cochrane Library at the CENTRAL Register of Controlled
Trials, Scielo) were searched from their inception until
April 2017.
METHODS OF STUDY SELECTION: We included all
randomized controlled trials comparing discontinuation
(ie, intervention group) and continuation (ie, control
group) of oxytocin infusion after the active phase of
labor is reached, either after induction or augmentation
of labor. Discontinuation of oxytocin infusion was
defined as discontinuing oxytocin infusion when the
active phase of labor was achieved. Continuation of
oxytocin infusion was defined as continuing oxytocin
infusion until delivery. Only trials in singleton gestations
with vertex presentation at term were included. The
primary outcome was the incidence of cesarean delivery.
TABULATION, INTEGRATION, AND RESULTS: Nine
randomized controlled trials, including 1,538 singleton
gestations, were identified as relevant and included in
the meta-analysis. All nine trials included only women
undergoing induction of labor. In the discontinuation
group, if arrest of labor occurred, usually defined as no
cervical dilation in 2 hours or inadequate uterine con-
tractions for 2 hours or more, oxytocin infusion was
restarted. Women in the control group had oxytocin
continued until delivery usually at the same dose used at
the time the active phase was reached. Women who
were randomized to have discontinuation of oxytocin
infusion after the active phase of labor was reached had
a significantly lower risk of cesarean delivery (9.3%
compared with 14.7%; relative risk 0.64, 95% CI 0.48–
0.87) and of uterine tachysystole (6.2% compared with
13.1%; relative risk 0.53, 95% CI 0.33–0.84) compared
with those who were randomized to have continuation
of oxytocin infusion until delivery. Discontinuation of
oxytocin infusion was associated with an increase in the
duration of the active phase of labor (mean difference
27.65 minutes, 95% CI 3.94–51.36).
CONCLUSION: In singleton gestations with cephalic
presentation at term undergoing induction, discontinu-
ation of oxytocin infusion after the active phase of labor
at approximately 5 cm is reached reduces the risk of
cesarean delivery and of uterine tachysystole compared
with continuous oxytocin infusion. Given this evidence,
discontinuation of oxytocin infusion once the active
stage of labor is established in women being induced




S ince it was first synthesized in the 1953, oxytocinhas become one of the most widely used medica-
tions in obstetrics to induce or to augment labor,
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utilized in up to 50% of deliveries in many countries.1
Different oxytocin regimens and protocols have been
described.2 Moreover, there are various studies look-
ing at optimal duration of oxytocin administration.
However, so far there is no consensus regarding
whether discontinuation of oxytocin, once the active
phase of labor is reached, may be an alternative man-
agement to continuous oxytocin infusion either after
induction or after augmentation of labor.
The aim of this study was to evaluate benefits and
harms of discontinuation compared with continuation of
oxytocin infusion after the active phase of labor is
reached. This review was performed according to a pro-
tocol designed a priori and recommended for systematic
reviews.3 Electronic databases (ie, MEDLINE, Scopus,
ClinicalTrials.gov, EMBASE, ScienceDirect, the Co-
chrane Library at the CENTRAL Register of Controlled
Trials, Scielo) were searched from their inception until
April 2017. Search terms used were the following text
words: “labor,” “labour,” “randomised,” “second stage,”
“randomized,” “oxytocin,” “continuation,” “discontinua-
tion,” “infusion,” “active phase,” “vaginal delivery,”
“effectiveness,” and “clinical trial.” No restrictions for
language or geographic location were applied. In addi-
tion, the reference lists of all identified articles were
examined to identify studies not captured by electronic
searches. The electronic search and the eligibility of
the studies were independently assessed by two authors
(G.S., V.B.). Differences were discussed and consensus
reached.
We included all randomized controlled trials
(RCTs) comparing discontinuation (ie, intervention
group) and continuation (ie, control group) of oxyto-
cin infusion after the active phase of labor is reached,
either after induction or after augmentation of labor.
Discontinuation of oxytocin infusion was defined as
discontinuing oxytocin infusion when the active phase
of labor was achieved. Continuation of oxytocin
infusion during the active phase of labor was defined
as continuing oxytocin infusion until delivery. Active
phase of labor was defined as per the original trial.
Only trials in singleton gestations with vertex pre-
sentation at term were included. Quasirandomized
trials (ie, trials in which allocation was done on the
basis of a pseudorandom sequence, eg, odd and even
hospital number or date of birth, alternation) were not
included. Trials in multiple gestations were also
excluded.
The risk of bias in each included study was
assessed by using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions. Seven
domains related to risk of bias were assessed in each
included trial because there is evidence that these
issues are associated with biased estimates of treatment
effect: 1) random sequence generation, 2) allocation
concealment, 3) blinding of participants and personnel,
4) blinding of outcome assessment, 5) incomplete out-
come data, 6) selective reporting, and 7) other bias.
Review authors’ judgments were categorized as “low
risk,” “high risk,” or “unclear risk” of bias.3
Two authors (G.S., A.C.) independently assessed
inclusion criteria, risk of bias, and data extraction.
Disagreements were resolved by discussion with
a third reviewer (V.B.).
All analyses were done using an intention-to-treat
approach, evaluating women according to the treatment
group to which they were randomly allocated in the
original trials. Primary and secondary outcomes were
defined before data extraction. The primary outcome
was the incidence of cesarean delivery. The secondary
outcomes were mean duration of the active phase, and
of the second stage of labor, incidence of vaginal
delivery, operative vaginal delivery, indications for
cesarean delivery, epidural analgesia, uterine tachysys-
tole, postpartum hemorrhage, chorioamnionitis, abnor-
mal fetal heart rate, and neonatal outcomes, including
birth weight, admission to the neonatal intensive care
unit, and Apgar score less than 7 at 5 minutes. All
authors were contacted for missing data, if possible.
Trials on oxytocin for induction of labor and trials on
oxytocin for augmentation of labor were analyzed
separately.
Subgroup analysis in nulliparous compared with
multiparous women was planned. We also performed
sensitivity analysis3 excluding trials with a high risk of
bias (ie, trials with more than one “high risk of bias” in
the Cochrane risk of bias tools)3 for the primary out-
come (ie, cesarean delivery).
The data analysis was completed independently by
two authors (G.S., V.B.) using Review Manager 5.3.3
The completed analyses were then compared, and any
difference was resolved by discussion. The summary
measures were reported as summary relative risk (RR)
or as summary mean difference with 95% CI using the
random-effects model of DerSimonian and Laird. Hig-
gins I 2 was used to identify heterogeneity.
Data from each eligible study were extracted
without modification of original data onto custom-
made data collection forms. A two-by-two table was
assessed for RR; for continuous outcomes, means6SD
were extracted and imported into Review Manager 5.3.
Potential publication bias was assessed statistically
by using Begg’s and Egger’s tests. P values ,.05 were
considered statistically significant.
The meta-analysis was reported following the
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and Meta-analyses (PRISMA) statement.4 The review
was registered with the PROSPERO International
Prospective Register of Systematic Reviews (registra-
tion No. CRD42017065683).
RESULTS
Nine RCTs, including 1,538 singleton gestations who
underwent induction of labor, were identified as
relevant and included in the meta-analysis (Appendix
1, available online at http://links.lww.com/AOG/
B22).5–13 Publication bias, assessed using Begg’s and
Egger’s tests, was not significant (P5.75 and .84,
respectively). Statistical heterogeneity between the tri-
als ranged from low (I 250%) to high (I 2596%) with
no inconsistency in risk estimates (I 250%) for the
primary outcome (ie, cesarean delivery) and most of
the secondary outcomes. Two authors kindly pro-
vided additional unpublished data from their trials.7,9
The quality of the RCTs included in our meta-
analysis was assessed by using the seven criteria
outlined in the Cochrane Handbook for Systematic Reviews
of Interventions.3 All the included studies had “low risk”
of bias in “random sequence generation,” except for
two in which details on methods used for randomiza-
tion were not reported. Adequate methods for alloca-
tion of women were used in five trials, whereas in four
RCTs, details on methods used to conceal allocation
were not reported (Appendix 2, available online at
http://links.lww.com/AOG/B22). Three trials5,8,13
used a placebo in the control group (500 mL of 0.
9% of NaCl solution). In four studies, randomization
was performed by using a computer-generated ran-
dom number sequence with sealed opaque envelopes
opened before dividing the women into the two
groups.6,7,9,12
The included trials came from both high-income
and low-income countries (Appendix 3, available
online at http://links.lww.com/AOG/B22). Years of
publication ranged from 2004 to 2015. Most of the
studies (seven of nine) were published in 2010 or after.
Only one trial came from the United States9 and only
one from Europe.7 Of the 1,538 women included, 764
(49.7%) were randomized in the intervention group
(ie, discontinuation of oxytocin infusion after the
active phase of labor was reached), and 774 (50.3%)
were randomized in the comparison group (ie, contin-
uation of oxytocin infusion even after the active phase
of labor was reached and until delivery). All trials
included only singleton gestations with vertex presen-
tation at 36 or more weeks of gestation who under-
went induction of labor. Women with “fetal distress”
at the time of randomization were excluded (Appen-
dix 3, http://links.lww.com/AOG/B22).
The definition of active phase was different
among the included trials, but in most of them, it
was defined as 5 cm or greater cervical dilation
(Appendix 4, available online at http://links.lww.
com/AOG/B22). Women in the intervention group
Fig. 1. Forest plot for the mean difference in duration of the active phase of labor in minutes, which was shorter by more
than 27 minutes in the oxytocin continuation group. IV, independent variable; df, degrees of freedom.
Saccone. Discontinuing Oxytocin During Labor. Obstet Gynecol 2017.
Fig. 2. Forest plot for the risk of cesarean delivery. M-H, Mantel-Haenszel test; df, degrees of freedom.
Saccone. Discontinuing Oxytocin During Labor. Obstet Gynecol 2017.
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had infusion of oxytocin discontinued when the active
phase was reached. In this group, if arrest of labor
occurred, usually defined as no cervical dilation in 2
hours or inadequate uterine contractions for 2 hours
or more, the oxytocin infusion was restarted (Appen-
dix 5, available online at http://links.lww.com/AOG/
B22). The percentages of women in the intervention
group who had oxytocin restarted ranged from 0% to
46.4% with a mean of 30% (140/461). In one study, 31
of 125 (24.8%) women in the intervention group did
not had oxytocin discontinued despite being random-
ized to the discontinuation group. Women in the con-
trol group had the infusion of oxytocin continued
until delivery usually at the same dose used at the time
the active phase reached, unless there was an indica-
tion to stop the infusion or to reduce the dosage, for
example, nonreassuring fetal heart rate tracing. The
percentages of women in the control group who had
oxytocin discontinued ranged from 0% to 7.7% with
a mean of 2% (15/567) (Appendix 5, http://links.lww.
com/AOG/B22).
In most of the included trials (Appendix 6, available
online at http://links.lww.com/AOG/B22), induction of
labor was started by oxytocin infusion of 1–2 milli-
international units/min (5 international units of oxytocin
diluted was usually diluted in 500 mL of 0.9 NaCl or of
Ringer’s solution). The dose was increased every 15–
20 minutes by 1–2 milli-international units/min until
regular contractions at a rate of three to five per 10 mi-
nutes were reached. In most of the included trials, the
maximum dose allowed was 20 milli-international units/
min (Appendix 6, http://links.lww.com/AOG/B22). In
case of an unfavorable Bishop score, cervical ripening
was used before or at the time of oxytocin induction of
labor, usually with misoprostol, or a Foley balloon
(Appendix 7, available online at http://links.lww.com/
AOG/B22).
By using an intention-to-treat approach, we found
that women who were randomized to have discontinu-
ation of oxytocin infusion after the active phase of labor
was reached had a longer length of active phase of labor
(mean difference 27.65 minutes, 95% CI 3.94–51.36;
Fig. 1), but similar duration of the second stage of labor
(Appendix 8, available online at http://links.lww.com/
AOG/B22), compared with those who were random-
ized to have continuation of oxytocin infusion until
Fig. 3. Forest plot for the risk of uterine tachysystole. M-H, Mantel-Haenszel test; df, degrees of freedom.
Saccone. Discontinuing Oxytocin During Labor. Obstet Gynecol 2017.
Table 1. Labor Outcomes
Duration of Active Phase of Labor (min) Duration of Second Stage (min)
Daniel-Spiegel, 200412 1566120 vs 1986174 31.863.6 vs 3063.6
Ustunyurt, 200713 111690 vs 101673 21.4635.6 vs 18.6615.9
Bahadoran, 20105 152.6647.3 vs 161.8687.7 47630 vs 43630.3
Rashwan, 201011 224633 vs 180640.4 45.16614.13 vs 36.269.86
Diven, 20129 2886210 vs 2226174* 30 (0–390) vs 30 (0–402)†
Begum, 20136 Not reported Not reported
Ozturk, 201410 1596105.9 vs 124681.0 Not reported
Bor, 20157 197.86181.9 vs 115.2694.5 Not reported
Chopra, 20158 510 vs 426‡ Not reported
I2 83% 80%
MD (95% CI)† 27.65 min (3.94–51.36) 4.46 min (20.08 to 9.01)
MD, mean difference.
Data are mean6SD or median (range) for number in the intervention group vs number in the control group unless otherwise specified.
Bold indicates statistical significance.
* Additional unpublished data kindly provided by the authors of the original trials.
† Data not included in the meta-analysis because mean and SD were not reported.
‡ Mean without SD was not included in the meta-analysis.
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delivery. Women in the intervention group had a signif-
icantly lower risk of cesarean delivery (9.3% compared
with 14.7%; RR 0.64, 95% CI 0.48–0.87; Fig. 2) and of
uterine tachysystole (6.2% compared with 13.1%; RR 0.
53, 95% CI 0.33–0.84; Fig. 3). No differences were
found in the incidence of abnormal fetal heart rate
(Appendix 9, available online at http://links.lww.com/
AOG/B22) and in the other secondary outcomes (Ta-
bles 1–3; Appendix 10 [Appendix 10 is available online
at http://links.lww.com/AOG/B22]).
Sensitivity analysis for the primary outcome,
including only RCTs with low risk of bias,6,9,11–13
Table 2. Mode of Delivery and Rate of Analgesia
Vaginal Delivery
Operative Vaginal
Delivery Cesarean Delivery* Epidural Analgesia
Daniel-Spiegel,
200412
47/52 (90.3) vs 44/52
(84.7)
2/52 (3.8) vs 3/52 (5.8) 3/52 (5.8) vs 6/52 (11.5) 29/52 (56.0) vs 29/52
(56.0)
Ustunyurt, 200713 160/168 (95.2) vs 162/174
(93.1)
Not reported 8/168 (4.8) vs 12/174 (6.9) Not reported
Bahadoran, 20105 Not reported Not reported Not reported Not reported
Rashwan, 201011 93/100 (93.0) vs 83/100
(83.0)
Not reported 7/100 (7) vs 17/100 (17) 41/100 (41.0) vs 100/100
(100)
Diven, 20129 96/125 (76.8) vs 94/127
(74.0)
5/125 (4.0) vs 1/127
(0.8)
24/125 (19.2) vs 32/127
(25.2)
118/125 (94.8) vs 122/127
(96.1)
Begum, 20136 44/50 (88.0) vs 40/50
(80.0)
4/50 (8.0) vs 2/50 (4.0) 2/50 (4.0) vs 8/50 (16.0) Not reported
Ozturk, 201410 Not reported Not reported Not reported Not reported
Bor, 20157 85/100 (85.0) vs 78/100
(78.0)
11/100 (11.0) vs 8/100
(8.0)
15/100 (15.0) vs 22/100
(22.0)
51/100 (51.0) vs 41/100
(41.0)
Chopra, 20158 46/53 (86.8) vs 45/53
(84.9)
6/53 (11.3) vs 8/53
(15.1)
1/53 (1.9) vs 0/56 Not reported
Total 571/648 (88.1) vs 546/656
(83.2)
28/380 (7.3) vs 22/382
(5.8)
60/648 (9.3) vs 97/659
(14.7)
239/377 (63.4) vs 292/379
(77.0)
I2 0% 0% 0% 96%
RR (95% CI) 1.05 (1.00–1.09) 1.20 (0.69–2.09) 0.64 (0.48–0.87) 0.84 (0.49–1.44)
RR, relative risk.
Data are n/N (%) for number in the intervention group vs number in the control group unless otherwise specified.
Bold indicates statistical significance.
*Primary outcome.
Table 3. Maternal and Fetal Complications
Uterine Tachysystole PPH Chorioamnionitis Abnormal FHR
Daniel-Spiegel,
200412
6/52 (12) vs 8/52 (16) Not reported Not reported 8/52 (15.4) vs 8/52 (15.4)
Ustunyurt, 200713 14/168 (8.3) vs 30/174
(17.2)
Not reported Not reported 4/168 (2.4) vs 6/174 (3.5)
Bahadoran, 20105 Not reported Not reported Not reported Not reported
Rashwan, 201011 0/100 vs 7/100 (7.0) Not reported Not reported 6/100 (6.0) vs 16/100 (16.0)
Diven, 20129 Not reported 8/125 (6.4) vs 8/127 (6.3) 16/125 (12.8) vs 7/127
(5.5)
7/125 (29.2) vs 8/127 (25.0)
Begum, 20136 Not reported 0/50 vs 6/50 (12.0) Not reported 4/50 (8.0) vs 6/50 (12.0)
Ozturk, 201410 4/66 (6.1) vs 6/64 (9.4) Not reported Not reported 10/66 (15.2) vs 5/64 (7.8)
Bor, 20157 Not reported 16/100 (16) vs 22/100 (22) Not reported 93/100 (93.0) vs 89/100 (89.0)
Chopra, 20158 Not reported Not reported Not reported 8/53 (15.1) vs 11/53 (20.7)
Total 24/386 (6.2) vs 51/390
(13.1)
8/175 (4.6) vs 14/177 (7.9) 16/125 (12.8) vs 7/127
(5.5)
140/714 (19.6) vs 149/720
(20.7)
I2 0% 69% Not applicable 44%
RR (95% CI) 0.53 (0.33–0.84) 0.39 (0.03–5.22) 2.32 (0.99–5.45) 0.87 (0.61–1.25)
PPH, postpartum hemorrhage; FHR, fetal heart rate; RR, relative risk.
Data are n/N (%) for number in the intervention group vs number in the control group unless otherwise specified.
Bold indicates statistical significance.
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concurred with the primary analysis (Appendix 11,
available online at http://links.lww.com/AOG/B22).
Planned subgroup analysis in nulliparous and multip-
arous women could not be assessed as a result of the
limited data available in these subsets of women.
DISCUSSION
This meta-analysis of nine RCTs, including 1,538
singleton gestations at term, showed that discontinu-
ation of oxytocin infusion after the active phase of
labor is reached reduces the risk of cesarean delivery
and of uterine tachysystole but lengthens the active
phase of labor. The rate of oxytocin restarted in the
oxytocin discontinuation group was 30%.
One prior meta-analysis has been published on
this issue. Vlachos et al14 in their review found a sig-
nificantly decreased rate of cesarean delivery among
women who discontinued oxytocin as well as
decreased rates of uterine tachysystole. This meta-
analysis differs from ours in the fact that not all trials
were included and statistics were different. Indeed,
Vlachos et al performed a systematic review without
a formal meta-analysis. Moreover, the two most
recent RCTs were not included with approximately
25% less women included in the review.
Our study has several limitations. Only one of
the included trials was from the United States, and
none was large. We could not perform subgroup
analysis by parity. We did not identify any trials on
discontinuation of oxytocin after augmentation of
labor, so the external validity of our data in this
population is unknown. Trials were somewhat
different in terms of oxytocin dosing and manage-
ment and delivery protocol. Only three RCTs5,8,13
used a placebo (500 mL of 0.9% of NaCl solution) in
the control group. Data on parity, cervical ripening,
and Bishop score were limited. At least half or more
than half of the included women were nulliparous,
when parity data were reported, but a separate anal-
ysis just on nulliparous or multiparous women was
not possible.
Different strategies have been adopted in labor
and delivery to improve the successful rate of
induction, reduce the length of labor as well as reduce
the risk of cesarean delivery.14–30 Since 1954, when it
was isolated and synthesized by Vincent du Vi-
gneaud, oxytocin has become the most widely used
obstetric agent for inducing or augmenting labor.24
However, despite the widespread use, there is no con-
sensus on its mode of administration.24,25 Two pre-
clinical studies have shown that after 10 hours of
oxytocin use, the myometrium receptor concentration
diminishes and further oxytocin administration has no
or a negative effect on myometrial contractility.26,27
Despite this evidence, continuous oxytocin infusion
during labor has been broadly adopted by the inter-
national obstetric community and recommended by
guidelines.28,29 Our study shows no difference in the
length of labor comparing discontinuing and discon-
tinuing oxytocin infusion after the active phase of
labor has been reached after induction of labor. This
may suggest that oxytocin-induced desensitization of
the oxytocin receptor, as shown in vitro,26,27 may also
occur in vivo. Once labor has entered the active phase
(eg, approximately 5 cm cervical dilation in most
included RCTs), further oxytocin seems not to be
associated with any benefit other than a shorter labor,
but indeed is associated with some harm.
In summary, in singleton gestations with
cephalic presentation at term, discontinuation of
oxytocin infusion after the active phase of labor is
reached reduces the risk of cesarean delivery and of
uterine tachysystole in women undergoing induc-
tion of labor. Given this evidence, discontinuation
of oxytocin infusion once the active stage of labor is
established in women being induced should
be considered as an alternative and efficacious
management plan.
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